dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Carles Galceran, Joan |
dc.contributor.author | Chowdhury, Simon |
dc.contributor.author | McGregor, Bradley |
dc.contributor.author | Merseburger, Axel |
dc.contributor.author | Agarwal, Neeraj |
dc.contributor.author | Azad, Arun |
dc.date.accessioned | 2022-08-11T06:09:05Z |
dc.date.available | 2022-08-11T06:09:05Z |
dc.date.issued | 2022-03 |
dc.identifier.citation | Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Futur Oncol. 2022 Mar;18(10):1185-98. |
dc.identifier.issn | 1479-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/7985 |
dc.description | Atezolizumab; Cabozantinib; Immune checkpoint inhibitor |
dc.description.abstract | Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy – a population with a significant unmet need for treatment options. |
dc.language.iso | eng |
dc.publisher | Future Medicine |
dc.relation.ispartofseries | Future Oncology;18(10) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer - Hormonoteràpia |
dc.subject | Metàstasi |
dc.subject.mesh | Prostatic Neoplasms, Castration-Resistant |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents, Hormonal |
dc.title | A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2217/fon-2021-1096 |
dc.subject.decs | neoplasias prostáticas resistentes a la castración |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos hormonales |
dc.relation.publishversion | https://doi.org/10.2217/fon-2021-1096 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Agarwal N] Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, USA. [Azad A] Peter MacCallum Cancer Centre & Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chowdhury S] Guy’s, King’s & St. Thomas’ Hospitals, & Sarah Cannon Research Institute, London, UK. [McGregor B] Lank Center of Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. [Merseburger AS] Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany |
dc.identifier.pmid | 35034502 |
dc.identifier.wos | 000743733200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |